New immunotherapy combo aims to shrink lung tumors before surgery
NCT ID NCT07122687
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This phase 2 trial tests whether adding an experimental immunotherapy (IBI363) or the approved drug Keytruda to chemotherapy before surgery can improve outcomes for people with stage IB to III non-squamous non-small cell lung cancer. About 170 participants will receive either IBI363 plus chemo or Keytruda plus chemo before their tumor is removed. The main goals are to see how many patients have no cancer left after treatment and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE STAGE IB-III NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Liaoning Cancer Hospital and Institute
RECRUITINGShenyang, Liaoning, 110000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBI363 (an experimental immunotherapy) and pembrolizumab (Keytruda, an approved immunotherapy)
What this could lead to
If successful, this could offer a new treatment option before surgery for certain lung cancers, potentially improving survival and reducing recurrence.
What could go wrong
This is a mid-stage trial with only 170 participants. The experimental drug IBI363 may not work better than Keytruda, and side effects from combining immunotherapy with chemotherapy can be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.